Three therapeutics for Alzheimer’s disease steal the headlines at the moment: Eisai and Biogen’s lecanemab, Genentech’s gantenerumab and Eli Lilly’s donanemab.
As Medtronic continues to await FDA clearance of the latest iteration of its MiniMed insulin pump, the medtech giant has churned out a steady stream of data supporting the device’s ability to improve outcomes for Type 1 diabetes patients.
Fresh off reporting promising results from a phase 3 study of its constipation relief device, Vibrant Gastro is keeping things moving.
Scientists have uncovered a link between chronic pain and lung cancer—a link that also offers a potentially druggable pathway for both conditions, according to new research conducted in mouse models.
Novo Nordisk is handing over $1.1 billion in cash to buy Forma Therapeutics in hopes that the clinical-stage biotech’s assets will help build a leading portfolio in sickle cell disease (SCD).
An administrative law judge ruled in Illumina’s favor Thursday in the U.S. Federal Trade Commission’s (FTC’s) challenge to the DNA sequencing giant’s acquisition of blood test maker Grail.
A week after taking back two unhatched inflammatory bowel assets from Takeda, Finch Therapeutics is cutting more than a third of its staff and delaying clinical trial plans to stave off rising costs.
The leadership and staffing shake-ups at Novartis continue to define the company’s year, with one of the most significant names yet electing to move on.
AnaptysBio’s stuttering effort to rebuild its pipeline around imsidolimab has hit another setback. After flopping in palmoplantar pustulosis and acne, the anti-IL-36 receptor antagonist has failed to move the needle in the chronic skin disease hidradenitis suppurativa, leading the biotech to stop work on one indication and plan to out-license the asset.
Mereo BioPharma, under pressure from an activist investor, has reduced its head count to stretch its cash runway out into the second quarter of 2025. The biotech disclosed the cuts in a rebuttal to Rubric Capital Management’s “low-risk strategy” for unlocking the value of its assets while preserving cash.